Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Fremanezumab for Cluster Headache (ENFORCE)
NCT03107052Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of fremanezumab in Cluster Headache (CH), sponsored by Teva Pharmaceutical Industries Ltd.. Started Apr 2017; status: terminated.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT03107052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107052.